-
Sagent gets OK for antibacterial drug
SCHAUMBURG, Ill. — Sagent has received approval from the Food and Drug Administration for its antibacterial drug.
The drug maker said that the FDA approved polymyxin B for injection USP. Sagent said that polymyxin B sulfate is used to treat infections of the urinary tract, meninges and bloodstream caused by susceptible strains of Pseudomonas aeruginosa.
The drug was developed in partnership with Strides Arcolab. Under the collaboration, Strides develops and supplies injectable products that Sagent will market in the United States.
-
UCB, Harvard enter research alliance focused on central nervous system, immunology
BOSTON and BRUSSELS — Drug maker UCB and Harvard University have entered a research alliance that is designed to advance ongoing Harvard research projects along the drug development pathway.
UCB said it will bring its expertise in antibody generation and medicinal chemistry into the alliance and will provide up to $6 million over two years to fund specific innovative research projects led by Harvard scientists. The collaboration focuses on the central nervous system and immunology, UCB said.